Skip to main content

Advertisement

Table 1 Participant characteristics

From: Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure

Parameter Value
Patients (n) 20
Male/female 20/0
Age (years) 66 ± 1
BMI (kg/m2) 31 ± 1
Diabetes duration (years) 13 ± 2
Microalbuminuria (20–200 µg/min) 7/20
 Mean (µg/min) 36 ± 18
Macroalbuminuria (>200 µg/min) 5/20
 Mean (µg/min) 368 ± 63
Diabetic retinopathy 16/20
 None 4
 Mild non-proliferative 7
 Moderate non-proliferative 7
 Severe non-proliferative 2
HbA1c (mmol/mol) 65 ± 4
Cholesterol (mmol/l) 4.1 ± 0.3
HDL-cholesterol (mmol/l) 1.0 ± 0.1
LDL-cholesterol (mmol/l) 2.4 ± 0.2
Triacylglycerol (mmol/l) 1.4 ± 0.1
eGFR (mL/min/1.73 m2) 64 ± 7
NYHA functional class (%)
 III 55
 IV 45
LV ejection fraction (%) 26 ± 2
Risk factors for heart failure (%)
 CAD 60
 Hypertension 80
 DCM 10
Smoking (%)
 Former smoker 60
 Current smoker 40
AF (%) 55
Concomitant medication (%)
 ACEi/A-II receptor antagonists 100
 Beta-blocker 95
 Loop diuretic 100
 Spironolactone 40
 ASA/clopidogrel 55
 Warfarin 55
Diabetes treatment (%)
 Insulin 60
 Metformin 25
 Sulphonylurea 5
 Combination therapy 5
 Diet only 15
  1. Values are mean ± standard error of the mean or proportions
  2. A-II receptor antagonists angiotensin-II receptor antagonists, ACEi angiotensin-converting enzyme inhibitor, ASA aspirin, AF atrial fibrillation, BMI body mass index, CAD coronary artery disease, DCM dilated cardiomyopathy, eGFR estimated glomerular filtration rate, HbA1c glycosylated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, LV left ventricular, CAD coronary artery disease, NYHA New York Heart Association